NO20071109L - Indol-2-karboksamidinderivater som NMDA-reseptorantagonister - Google Patents
Indol-2-karboksamidinderivater som NMDA-reseptorantagonisterInfo
- Publication number
- NO20071109L NO20071109L NO20071109A NO20071109A NO20071109L NO 20071109 L NO20071109 L NO 20071109L NO 20071109 A NO20071109 A NO 20071109A NO 20071109 A NO20071109 A NO 20071109A NO 20071109 L NO20071109 L NO 20071109L
- Authority
- NO
- Norway
- Prior art keywords
- halogen atom
- indole
- optionally substituted
- carboxamidine derivatives
- atom
- Prior art date
Links
- NUNZGJKXTJMXGY-UHFFFAOYSA-N 1H-indole-2-carboximidamide Chemical class C1=CC=C2NC(C(=N)N)=CC2=C1 NUNZGJKXTJMXGY-UHFFFAOYSA-N 0.000 title abstract 3
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 125000002905 alkanoylamido group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- PNDKCRDVVKJPKG-WHERJAGFSA-N cenicriviroc Chemical compound C1=CC(OCCOCCCC)=CC=C1C1=CC=C(N(CC(C)C)CCC\C(=C/2)C(=O)NC=3C=CC(=CC=3)[S@@](=O)CC=3N(C=NC=3)CCC)C\2=C1 PNDKCRDVVKJPKG-WHERJAGFSA-N 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
Abstract
Den foreliggende oppfinnelse vedrører for det første nye indol-2-karboksamidinderivater med formel (I) hvor betydningen av X er hydrogen- eller halogen-atom, CpC4-alkyl-, CrC4-alkoksy- eller trifluor-metylgruppe, Y, V og Z er uavhengig av hverandre hydrogen- eller halogenatom, hydroksy, cyano, Cp C4-alkylsulfonamido som eventuelt er substituert med et halogenatom eller halogenatomer, CVC4-alkanoylamido som eventuelt er substituert med et halogenatom eller halogenatomer, trifluormetyl-, trifluormetoksy-, CrC4-alkyl- eller Ci-C4-alkoksy-gruppe, eller de nabostilte V- og Z-grupper kan i et bestemt tilfelle sammen med ett eller flere identiske eller forskjellige, ytterligere heteroatomer og -CH= og/eller -CH2-grupper danne en eventuelt substituert 4-7-leddet homo- eller heterosyklisk ring, fortrinnsvis en benzen- eller dioksolanring, A, B og C er uavhengig av hverandre substituert karbon-atom eller en av dem er nitrogenatom, og saltene derav. Ytterligere gjenstander for oppfinnelsen er fremgangsmåtene for fremstilling av indol-2-karboksamidinderivater med formel (I), og den farmasøytiske fremstillingen av medikamenter som inneholder disse forbindelsene, samt fremgangsmåten for behandlinger med disse forbindelsene, det vil si administrering til et pattedyr som skal behandles, inkludert et menneske, av en effektiv
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0401523A HUP0401523A3 (en) | 2004-07-29 | 2004-07-29 | Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them |
PCT/HU2005/000078 WO2006010965A1 (en) | 2004-07-29 | 2005-07-21 | Indole-2 -carboxamidine derivatives as nmda receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20071109L true NO20071109L (no) | 2007-02-27 |
Family
ID=89985408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20071109A NO20071109L (no) | 2004-07-29 | 2007-02-27 | Indol-2-karboksamidinderivater som NMDA-reseptorantagonister |
Country Status (21)
Country | Link |
---|---|
US (1) | US20090048303A1 (no) |
EP (1) | EP1773770B1 (no) |
JP (1) | JP2008508248A (no) |
KR (1) | KR20070038502A (no) |
CN (1) | CN1989103A (no) |
AP (1) | AP2006003840A0 (no) |
AT (1) | ATE427299T1 (no) |
AU (1) | AU2005266160A1 (no) |
BR (1) | BRPI0513932A (no) |
CA (1) | CA2574155A1 (no) |
DE (1) | DE602005013675D1 (no) |
EA (1) | EA009981B1 (no) |
GE (1) | GEP20094606B (no) |
HU (1) | HUP0401523A3 (no) |
IL (1) | IL179485A0 (no) |
MA (1) | MA28815B1 (no) |
MX (1) | MX2007001052A (no) |
NO (1) | NO20071109L (no) |
TN (1) | TNSN07016A1 (no) |
WO (1) | WO2006010965A1 (no) |
ZA (1) | ZA200700325B (no) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
EP2536713A1 (en) | 2010-02-16 | 2012-12-26 | Pfizer Inc. | (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors |
US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
US9562038B2 (en) * | 2010-11-18 | 2017-02-07 | Yale University | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus |
EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
US9669030B2 (en) * | 2012-05-22 | 2017-06-06 | Autifony Therapeutics Limited | Hydantoin derivatives as Kv3 inhibitors |
JO3579B1 (ar) | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
WO2019022179A1 (ja) * | 2017-07-28 | 2019-01-31 | 武田薬品工業株式会社 | 複素環化合物 |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9726388D0 (en) * | 1997-12-12 | 1998-02-11 | Cerebrus Ltd | Chemical compounds |
US6319944B1 (en) * | 1999-05-10 | 2001-11-20 | Merck & Co., Inc. | Aryl amidines, compositions containing such compounds and methods of use |
US6376530B1 (en) * | 1999-05-10 | 2002-04-23 | Merck & Co., Inc. | Cyclic amidines useful as NMDA NR2B antagonists |
GB0015488D0 (en) * | 2000-06-23 | 2000-08-16 | Merck Sharp & Dohme | Therapeutic agents |
HU227197B1 (en) * | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
JP2004253425A (ja) * | 2003-02-18 | 2004-09-09 | Tdk Corp | 積層コンデンサ |
-
2004
- 2004-07-29 HU HU0401523A patent/HUP0401523A3/hu unknown
-
2005
- 2005-07-21 CN CNA2005800247658A patent/CN1989103A/zh active Pending
- 2005-07-21 AP AP2006003840A patent/AP2006003840A0/xx unknown
- 2005-07-21 AU AU2005266160A patent/AU2005266160A1/en not_active Abandoned
- 2005-07-21 DE DE602005013675T patent/DE602005013675D1/de not_active Expired - Fee Related
- 2005-07-21 JP JP2007523161A patent/JP2008508248A/ja not_active Withdrawn
- 2005-07-21 BR BRPI0513932-5A patent/BRPI0513932A/pt not_active IP Right Cessation
- 2005-07-21 MX MX2007001052A patent/MX2007001052A/es active IP Right Grant
- 2005-07-21 WO PCT/HU2005/000078 patent/WO2006010965A1/en active Application Filing
- 2005-07-21 EA EA200700365A patent/EA009981B1/ru not_active IP Right Cessation
- 2005-07-21 CA CA002574155A patent/CA2574155A1/en not_active Abandoned
- 2005-07-21 GE GEAP20059893A patent/GEP20094606B/en unknown
- 2005-07-21 KR KR1020077000263A patent/KR20070038502A/ko not_active Application Discontinuation
- 2005-07-21 US US11/658,787 patent/US20090048303A1/en not_active Abandoned
- 2005-07-21 EP EP05764412A patent/EP1773770B1/en active Active
- 2005-07-21 AT AT05764412T patent/ATE427299T1/de not_active IP Right Cessation
-
2006
- 2006-11-22 IL IL179485A patent/IL179485A0/en unknown
-
2007
- 2007-01-11 ZA ZA200700325A patent/ZA200700325B/en unknown
- 2007-01-17 TN TNP2007000016A patent/TNSN07016A1/en unknown
- 2007-02-22 MA MA29702A patent/MA28815B1/fr unknown
- 2007-02-27 NO NO20071109A patent/NO20071109L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20070038502A (ko) | 2007-04-10 |
WO2006010965A1 (en) | 2006-02-02 |
US20090048303A1 (en) | 2009-02-19 |
IL179485A0 (en) | 2007-05-15 |
HUP0401523A2 (en) | 2006-11-28 |
CA2574155A1 (en) | 2006-02-02 |
ZA200700325B (en) | 2008-05-28 |
HU0401523D0 (en) | 2004-09-28 |
EA200700365A1 (ru) | 2007-06-29 |
HUP0401523A3 (en) | 2007-05-02 |
JP2008508248A (ja) | 2008-03-21 |
MA28815B1 (fr) | 2007-08-01 |
EA009981B1 (ru) | 2008-04-28 |
DE602005013675D1 (de) | 2009-05-14 |
AP2006003840A0 (en) | 2006-12-31 |
AU2005266160A1 (en) | 2006-02-02 |
TNSN07016A1 (en) | 2008-06-02 |
EP1773770B1 (en) | 2009-04-01 |
ATE427299T1 (de) | 2009-04-15 |
BRPI0513932A (pt) | 2008-05-20 |
MX2007001052A (es) | 2007-04-16 |
CN1989103A (zh) | 2007-06-27 |
EP1773770A1 (en) | 2007-04-18 |
GEP20094606B (en) | 2009-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20071109L (no) | Indol-2-karboksamidinderivater som NMDA-reseptorantagonister | |
DE60320012D1 (de) | Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen | |
NO20064201L (no) | Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling | |
NO20062726L (no) | Nye pyridazin-3(2H)-on derivater | |
NO20071140L (no) | Nye piperidinderivater som histamin H3 reseptorligander for behandling av depresjon | |
TNSN05194A1 (en) | Substituted n-arylheterocycles, method for production and use thereof as medicaments | |
NO20061839L (no) | Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav | |
WO2001064639A3 (en) | Pde iv inhibiting amides, compositions and pharmaceutical use | |
NO20066055L (no) | Pyridinderivater | |
ATE365742T1 (de) | 4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren | |
NO20050828L (no) | lndol-3-svovelderivater | |
TW200621762A (en) | Novel compounds | |
NO20061363L (no) | Pyrazolo- og imidazo- pyrimidinderivater | |
NO20060147L (no) | Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav | |
ATE418551T1 (de) | Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia | |
NO20060146L (no) | Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav | |
WO2007122634A3 (en) | Pyrimidinediones as tyrosine kinase inhibitors | |
DE602008001725D1 (de) | 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus | |
NO20076695L (no) | Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser | |
NO20070837L (no) | Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer. | |
ATE406364T1 (de) | Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia | |
BRPI0517100A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, método para preparar um composto, composição farmacêutica, e, métodos para tratar um paciente sofrendo de distúrbios e de deficiência | |
NO20055749L (no) | Sulfamat benzotiofenderivater som steroid sulfatase inhibitorer | |
NO20052491L (no) | Nye vitronektinresepotr antagonistderivater, fremgangsmate til deres fremstilling, anvendelse derav som legemidler og farmasoytiske sammensetninger som inneholder de samme | |
WO2008106125A3 (en) | Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |